Feeds:
Posts
Comments

Archive for May, 2010

URO TODAY: To screen for prostate cancer, or not to screen? Two experts in the US put opposing cases. READ MORE>

Read Full Post »

URO TODAY: The surge in adoption of robotic-assisted radical prostatectomy – across the United States in particular – has put “open” surgeons on the defensive. READ MORE>

Read Full Post »

URO TODAY: What do you do when you’re told you have prostate cancer – get treatment or wait and watch? A bunch of US experts have been debating the pros and cons of active surveillance. READ MORE>

Read Full Post »

AMERICAN JOURNAL OF MEDICINE: To reduce morbidity and mortality from prostate cancer and breast cancer, new approaches for screening, early detection, and prevention for both diseases should be considered. READ MORE> (but you need to pay $US30 to get access to the full text).

URO TODAY: The need for this aprioristic rethinking is manifest, very eminently, in the fresh recommendations about screening for breast cancer, issued by the US Preventive Services Task Force, and in the public uproar provoked by these. READ MORE>

Read Full Post »

NEWS-PRESS.COM: A new device being used for radiotherapy in the US targets the prostate and tracks it, even if it (presumably the patient) shifts positions during treatment.

 If it does shift, the machine prompts the technician or physician using it to shut off the radiation. READ MORE>

Read Full Post »

URO TODAY: The stigma associated with prostate cancer and its aftermath needs much more research, a recent conference in Spain was told.

Men are reticent to discuss sexual or urinary problems, are reluctant to seek medical help and men’s health is not as prominent in the public eye or in the public agenda. READ MORE>

Read Full Post »

US PROSTATE CANCER FOUNDATION: Provenge appears to extend survival in men with advanced prostate cancer, and it does so without the serious side effects associated with chemotherapy, radiation and hormone therapy. READ MORE>

Read Full Post »

URO TODAY: Technological difficulties must be addressed before an efficient and safe gene medicine using immunotherapy is achieved (primarily by developing a means of delivering genes to the target cells or tissue safely and efficiently). READ MORE>

Read Full Post »

URO TODAY:  Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have  not had chemotherapy.

A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>

Read Full Post »

URO TODAY: Men with low-risk prostate cancer undergoing active surveillance have a bigger risk for cancer recurrence if they are older, obese or had exposure to Agent Orange. READ MORE>

Read Full Post »

Older Posts »